Table 3.
Comparison of serum fibroblast growth factor-23 and miR-208b in different subgroups of observation group
| Group | n | Man, n (%) | Age (yr) | FGF-23 (ng/mL) | Relative expression of miR-208b | LAD (mm) | LVEDD (mm) | LVESD (mm) | LVEF (%) |
| Paroxysmal atrial fibrillation | 134 | 98 (73.13) | 61.02 ± 10.11 | 191.20 ± 65.59 | 4.88 ± 1.02 | 34.03 ± 4.02 | 50.03 ± 6.03 | 32.10 ± 5.58 | 53.30 ± 7.81 |
| Persistent atrial fibrillation | 106 | 70 (66.04) | 59.89 ± 9.92 | 234.22 ± 70.05 | 5.83 ± 1.00 | 38.81 ± 5.11 | 49.81 ± 5.82 | 32.01 ± 6.02 | 52.83 ± 8.10 |
| t | 1.419 | 0.867 | -4.896 | -7.227 | -8.112 | 0.285 | 0.120 | 0.455 | |
| P value | 0.234 | 0.387 | 0.000 | 0.000 | 0.000 | 0.776 | 0.905 | 0.649 |
FGF: Fibroblast growth factor; LAD: Left atrial dimension; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end-systolic diameter.